Search results for "OSA"

showing 10 items of 9388 documents

Meaning in life is associated with the psychopathology of eating disorders: differences depending on the diagnosis

2019

Previous studies indicated that meaning in life was inversely associated with eating behaviors and a negative attitude toward food, body satisfaction, and borderline symptoms. However, research on the association between meaning in life and eating disorder psychopathology is scarce, and there are no studies on the association between meaning in life and the eating disorder psychopathology depending on the diagnosis. The aim of the present study is to verify whether meaning in life is differentially associated with a broad range of psychopathology symptoms commonly observed in people with ED, depending on the diagnosis, in a sample of 240 ED patients. We found that meaning in life was negati…

AdultMale050103 clinical psychologyAnorexia NervosaPersonal SatisfactionAnorexia nervosaFeeding and Eating DisordersYoung Adult03 medical and health sciences0302 clinical medicineNegatively associatedSurveys and QuestionnairesmedicineHumans0501 psychology and cognitive sciencesMeaning (existential)Young adultBulimia NervosaAssociation (psychology)Trastorns de la conducta alimentàriaPsychopathologyVidadigestive oral and skin physiology05 social sciencesAnorèxia nerviosaFeeding BehaviorGeneral MedicineExplained variationmedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyEating disordersPsicologia pedagògicaFemalePsychologyActitud (Psicologia)Clinical psychologyPsychopathologyEating Disorders
researchProduct

Attitudes towards change mediate the effect of dissociation on psychopathological outcome in the treatment of eating disorders.

2020

Objectives The study aimed to examine whether dissociation and attitudes towards change were associated with the psychopathology in patients with eating disorders (EDs) at 1-year follow-up. Method The study included 110 females with anorexia nervosa and bulimia nervosa (48 and 62 respectively). At the beginning of the study and 1 year later, they were assessed by means of the following questionnaires: Dissociative Experiences Scale, Attitudes Towards Change (ACTA), State-Trait Anxiety Inventory, Rosenberg Self-Esteem Scale, Beck Depression Inventory, Eating Attitude Test, Bulimic Investigatory Test Edinburgh and Body Shape Questionnaire (BSQ). Results No statistically significant difference…

AdultMale050103 clinical psychologyDissociation (neuropsychology)Anorexia NervosaDissociative Experiences ScaleDissociative DisordersFeeding and Eating Disorders03 medical and health sciencesYoung Adult0302 clinical medicinemental disordersmedicineHumans0501 psychology and cognitive sciencesIn patientBulimia NervosaPsychopathologyBulimia nervosa05 social sciencesBeck Depression Inventorymedicine.disease030227 psychiatryPsychiatry and Mental healthClinical PsychologyEating disordersTreatment OutcomeAttitudeAnxietyFemalemedicine.symptomPsychologyPsychopathologyClinical psychologyEuropean eating disorders review : the journal of the Eating Disorders AssociationREFERENCES
researchProduct

Validity of the compulsive exercise test in regular exercisers.

2019

Measurement of compulsive exercise is important for the study of eating pathology in individuals who regularly participate in sport and exercise. The current study examined the factor structure, internal consistency and validity of the compulsive exercise test (CET) in regular exercisers. Participants were recruited via the internet and from sport clubs (

AdultMale050103 clinical psychologyExcessive exerciseAnorexia nervosaCompulsive ExerciseFeeding and Eating Disorders03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesmedicineHumans0501 psychology and cognitive sciencesExercise05 social sciencesEating pathologyGeneral Medicinemedicine.disease030227 psychiatryTest (assessment)Psychiatry and Mental healthClinical PsychologyEating disordersFemalePsychologyhuman activitiesPsychopathologyClinical psychologySportsEating disorders
researchProduct

Influence of Weight on Shared Core Symptoms in Eating Disorders

2016

In terms of the transdiagnostic model of eating disorders, Anorexia Nervosa (AN), Bulimia Nervosa (BN), and Binge Eating Disorder (BED) share the same distinctive psychopathology. However, empirical evidence showing similarities between these eating disorder diagnoses for core symptoms is scarce, and the role of weight status is unclear. Data from a total of 168 female participants were collected between April 2004 and April 2008, at an outpatient unit specialized in eating disorder treatment. Core symptoms of eating disorders were measured via self-report questionnaires. In particular, women with BED and BN showed similar patterns of core symptomatology compared with AN. However, when body…

AdultMale050103 clinical psychologymedicine.medical_specialtyAdolescentAnorexia nervosaBody Mass IndexFeeding and Eating DisordersYoung Adult03 medical and health sciences0302 clinical medicineArts and Humanities (miscellaneous)Binge-eating disorderBody ImageDevelopmental and Educational PsychologymedicineHumans0501 psychology and cognitive sciencesPsychiatryAgedBulimia nervosaBody Weightdigestive oral and skin physiology05 social sciencesPerspective (graphical)Feeding BehaviorMiddle Agedmedicine.disease030227 psychiatryClinical PsychologyEating disordersFemaleSymptom AssessmentCore symptomsPsychologyBody mass indexPsychopathologyClinical psychologyBehavior Modification
researchProduct

A multicenter audit of outpatient care for adult anorexia nervosa: Symptom trajectory, service use, and evidence in support of “early stage” versus “…

2020

Background: We explored the utility of “staging” anorexia nervosa (AN) by duration of illness and psychological wellbeing. We also investigated 12-month symptom trajectories and service usage in a large cohort of patients with AN assessed for outpatient treatment. Method: We conducted secondary analyses on data from a multisite clinical trial of adults with AN (n = 187) recruited from 22 NHS England specialist eating disorder (ED) services into a digital treatment augmentation study. Clinical outcomes and service use were measured at postintervention (six weeks), 6 and 12 months. We grouped patients into two categories: “early stage” (illness duration <3 years; n = 60) and “severe and en…

AdultMale050103 clinical psychologymedicine.medical_specialtyanorexia nervosa classification illness duration outpatient care social adjustment staging treatment outcomessocial adjustmentillness durationtreatment outcomesanorexia nervosa03 medical and health sciences0302 clinical medicineAmbulatory careSettore M-PSI/08 - Psicologia ClinicaAmbulatory CaremedicineHumans0501 psychology and cognitive sciencesoutpatient careDASSbusiness.industry05 social sciencesstaging030227 psychiatryClinical trialPsychiatry and Mental healthDistressMoodclassificationAnorexia nervosa (differential diagnoses)anorexia nervosa; classification; illness duration; outpatient care; social adjustment; staging; treatment outcomesPhysical therapyAnxietyFemalemedicine.symptombusinessBody mass index
researchProduct

Phenotypical features of two patients diagnosed with PHARC syndrome and carriers of a new homozygous mutation in the ABHD12 gene.

2018

Abstract PHARC (Polyneuropathy, Hearing loss, Ataxia, Retinitis pigmentosa and Cataracts) (MIM# 612674 ) is an autosomal recessive neurodegenerative disease caused by mutations in the ABHD12 gene. We evaluated two Spanish siblings affected with pes cavus, sensorimotor neuropathy, hearing loss, retinitis pigmentosa and juvenile cataracts in whom the genetic test of ABHD12 revealed a novel homozygous frameshift mutation, c.211_223del (p.Arg71Tyrfs*26). The earliest clinical manifestation in these patients was a demyelinating neuropathy manifested with a Charcot-Marie-Tooth phenotype over three decades. Progressive hearing loss, cataracts and retinitis pigmentosa appeared after the age of 30. …

AdultMaleARLID12 genecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyAtaxiagenetic structuresHearing lossUsher syndromeCharcot-Marie-Tooth diseaseCataractFrameshift mutation03 medical and health sciencesPolyneuropathies0302 clinical medicineCataractsRetinitis pigmentosaotorhinolaryngologic diseasesmedicineHumansMuscle SkeletalDeaf-blindnessbusiness.industryPHARCBrainmedicine.diseaseDermatologyMagnetic Resonance Imagingeye diseasesMonoacylglycerol LipasesPedigreePhenotypeNeurologySpainMutation030221 ophthalmology & optometryAtaxiasense organsNeurology (clinical)medicine.symptombusinessUsher syndromePolyneuropathy030217 neurology & neurosurgeryRetinitis PigmentosaRetinopathyJournal of the neurological sciences
researchProduct

Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – Implications for the evaluation of …

2013

Quercetin has been shown to inhibit intestinal P-glycoprotein-mediated drug efflux. A crossover clinical study was performed in 10 healthy volunteers to assess the effect of single-dose and repeated quercetin intake on the pharmacokinetics of talinolol, a substrate of intestinal P-glycoprotein. Unexpectedly, mean area under the plasma concentration-time curve (AUC0-48h) and maximal plasma concentration (cmax) were slightly decreased following concomitant and short-term quercetin administration (3186.0 versus 2468.3 and 2527.7 ng h/ml, p>0.05; 309.7 versus 212.0 and 280.6 ng/ml, p>0.05). Individual analysis revealed that talinolol AUC0-48h was lowered by 23.9% up to 60.6% in 5 subjects and c…

AdultMaleATP Binding Cassette Transporter Subfamily BFlavonoidCmaxAdministration OralPharmaceutical SciencePharmacologyDrug Administration SchedulePropanolaminesYoung Adultchemistry.chemical_compoundPharmacokineticsHumansDrug Interactionsheterocyclic compoundsIntestinal MucosaP-glycoproteinchemistry.chemical_classificationCross-Over StudiesDose-Response Relationship DrugbiologyBiological TransportTransporterMiddle AgedHealthy VolunteersIntestineschemistrybiology.proteinFemaleQuercetinEffluxQuercetinTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

A case of bowel schistosomiasis not adhering to endoscopic findings

2005

Schistosomiasis is a chronic worm infection caused by a species of trematodes, the Schistosomes. We may distinguish a urinary form from Schistosomes haematobium and an intestinal-hepatosplenic form mainly from Schistosomes mansoni characterized by nausea, meteorism, abdominal pain, bloody diarrhea, rectal tenesmus, and hepatosplenomegaly. These infections represent a major health issue in Africa, Asia, and South America, but recently S mansoni has increased its prevalence in other continents, such as Europe countries and North America, due to international travelers and immigrants, with several diagnostic and prevention problems. We report a case of a 24-year-old patient without HIV infecti…

AdultMaleAbdominal painmedicine.medical_specialtySettore MED/09 - Medicina InternaHepatosplenomegalyColonoscopyCase ReportSchistosomiasisGastroenterologyPraziquantelFeceschemistry.chemical_compoundMesalazineIntestinal mucosaInternal medicineparasitic diseasesmedicineAnimalsHumansIntestinal MucosaParasite Egg CountSchistosomaAnthelminticsbiologymedicine.diagnostic_testGastroenterologybowel schistosomiasis; endoscopic findingsGeneral Medicinebiology.organism_classificationmedicine.diseaseRectal tenesmusSchistosomiasis mansonichemistryImmunologySchistosomamedicine.symptomWorld Journal of Gastroenterology
researchProduct

Effects of controlled-release on the pharmacokinetics and absorption characteristics of a compound undergoing intestinal efflux in humans

2006

Abstract Objective The number of active pharmaceutical ingredients (API) undergoing inhibitable and saturable intestinal efflux is considerable. As a consequence, absorption and bioavailability may depend on the intestinal concentration profile of the drug and may vary as a function of dose and release rate of the drug from the dosage form. The impact of controlled versus immediate-release on the absorption of P-glycoprotein substrates is currently unknown. Thus, the main focus of the present study was a comparison of the pharmacokinetics of the P-gp model substrate talinolol following administration of immediate-release (IR) and controlled-release (CR) tablets to healthy human volunteers w…

AdultMaleActive ingredientChemistryPharmaceutical ScienceAbsorption (skin)PharmacologyCrossover studyControlled releaseDosage formBioavailabilityPropanolamineschemistry.chemical_compoundIntestinal AbsorptionSolubilityPharmacokineticsDelayed-Action PreparationsHumansFemaleATP Binding Cassette Transporter Subfamily B Member 1TabletsTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Treatment of painful radiculopathies with capsaicin 8% cutaneous patch.

2017

The treatment of neuropathic pain due to low-back (lumbosacral) radiculopathies, a common source of neuropathic pain, is challenging and often requires a multimodal therapeutic approach. The capsaicin 8% patch is the first topical analgesic licensed for peripheral neuropathic pain. To evaluate this treatment, a subset of patients with painful radiculopathy (lumbar and cervical, including ventral and dorsal rami) enrolled into the multicenter, non-interventional QUEPP study (QutenzaOf the 1044 study participants, 50 were diagnosed with painful radiculopathy as only peripheral neuropathic pain syndrome and were eligible for evaluation. Patients received a single treatment (visit 1) with follo…

AdultMaleAdministration Cutaneous03 medical and health sciences0302 clinical medicineLumbarQuality of life030202 anesthesiologySurveys and QuestionnairesMedicineHumansRadiculopathyAgedReferred painbusiness.industryPruritusGeneral MedicineMiddle Agedmedicine.diseaseLow back painSpineTreatment OutcomeAnesthesiaNeuropathic painNeuralgiaQuality of LifeNeuralgiaFemalemedicine.symptomCapsaicinbusinessRadiculopathies030217 neurology & neurosurgeryLumbosacral jointCurrent medical research and opinion
researchProduct